Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

('Tissue Regenix', or the 'Company')

Multi-year distribution agreement for OrthoPure® XT signed in the UK

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that it has signed an exclusive distribution agreement with Joint Operations Ltd ('Joint Operations'), a leading distribution business in the UK supplying numerous products to treat joint injuries and help to preserve the joints of the body, for the distribution of the Tissue Regenix OrthoPure® XT product in the United Kingdom.

The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure® XT to its portfolio of products. Joint Operations already distributes orthopaedic equipment to the National Health Service and the private sector within the UK, offering clinicians comprehensive orthopaedic solutions around joint reconstruction and preservation surgeries.

The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL® technology and is the only available, non-human biologic graft for certain anterior cruciate ligament ('ACL') reconstruction procedures on the market. OrthoPure® XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.

Richard Forster, Managing Director of Joint Operations Ltd, commented on the agreement: "We are delighted to be working with Tissue Regenix to represent OrthoPure® XT in the UK. As a company, we spend a great deal of time in ligament reconstructive surgery, and it is tremendously exciting to have a unique xenograft option to offer UK surgeons. In particular, we have been impressed by the quality of clinical outcomes being achieved through the Tissue Regenix clinical studies, and we look forward to these results being replicated nationwide over the coming years."

Daniel Lee, Chief Executive Officer of Tissue Regenix, said: "We are excited to partner with Joint Operations, who are experts in the distribution of orthopaedic equipment within the UK where an estimated 30,000 ACL surgeries take place each year1. This strategic partnership will continue our reach into the UK, ensuring these markets have access to our pioneering medical technology, which will help to transform patient care."

1 Beard, DJ. SNNAP Trial NDorms Oxford The Lancet, August 2022; https://www.ndorms.ox.ac.uk/news/ACL-SSNAP-trial-results

For more information:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.